Trial Outcomes & Findings for Clinical Comparison of Two Daily Disposable Contact Lenses (NCT NCT04865354)

NCT ID: NCT04865354

Last Updated: 2022-07-06

Results Overview

Distance visual acuity (VA) was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

170 participants

Primary outcome timeframe

Day 8, each study lens type

Results posted on

2022-07-06

Participant Flow

This study was conducted at 8 investigative sites in the United States.

Of the 170 enrolled, 3 subjects were exited prior to randomization as screen failures. This reporting group includes all randomized subjects (167).

Participant milestones

Participant milestones
Measure
PRECISION1, Then Clariti 1-Day
Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
Clariti 1-Day, Then PRECISION1
Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
First Wear Period (8 Days)
STARTED
83
84
First Wear Period (8 Days)
COMPLETED
82
83
First Wear Period (8 Days)
NOT COMPLETED
1
1
Second Wear Period (8 Days)
STARTED
82
83
Second Wear Period (8 Days)
COMPLETED
81
83
Second Wear Period (8 Days)
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
PRECISION1, Then Clariti 1-Day
Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
Clariti 1-Day, Then PRECISION1
Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
First Wear Period (8 Days)
Withdrawal by Subject
1
0
First Wear Period (8 Days)
Lost to Follow-up
0
1
Second Wear Period (8 Days)
Protocol deviation, dispensed wrong powers
1
0

Baseline Characteristics

Clinical Comparison of Two Daily Disposable Contact Lenses

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PRECISION1, Then Clariti 1-Day
n=83 Participants
Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
Clariti 1-Day, Then PRECISION1
n=84 Participants
Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
Total
n=167 Participants
Total of all reporting groups
Age, Continuous
31.3 years
STANDARD_DEVIATION 8.9 • n=99 Participants
31.4 years
STANDARD_DEVIATION 7.5 • n=107 Participants
31.4 years
STANDARD_DEVIATION 8.2 • n=206 Participants
Sex: Female, Male
Female
54 Participants
n=99 Participants
62 Participants
n=107 Participants
116 Participants
n=206 Participants
Sex: Female, Male
Male
29 Participants
n=99 Participants
22 Participants
n=107 Participants
51 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=99 Participants
8 Participants
n=107 Participants
13 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
78 Participants
n=99 Participants
76 Participants
n=107 Participants
154 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race/Ethnicity, Customized
White
69 Participants
n=99 Participants
67 Participants
n=107 Participants
136 Participants
n=206 Participants
Race/Ethnicity, Customized
Black or African American
1 Participants
n=99 Participants
3 Participants
n=107 Participants
4 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian
12 Participants
n=99 Participants
13 Participants
n=107 Participants
25 Participants
n=206 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Region of Enrollment
United States
83 participants
n=99 Participants
84 participants
n=107 Participants
167 participants
n=206 Participants

PRIMARY outcome

Timeframe: Day 8, each study lens type

Population: Full Analysis Set: All randomized subjects who are exposed to any study lenses evaluated in this study with non-missing response (eye)

Distance visual acuity (VA) was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity.

Outcome measures

Outcome measures
Measure
PRECISION1
n=328 eyes
Verofilcon A contact lenses worn bilaterally (in both eyes) during Period 1 or Period 2, as randomized, for 8 days in a daily disposable modality
Clariti 1-Day
n=328 eyes
Somofilcon A contact lenses worn bilaterally (in both eyes) during Period 1 or Period 2, as randomized, for 8 days in a daily disposable modality
Least Squares Mean Distance VA (logMAR) With Study Lenses
-0.119 logMAR
Standard Error 0.0055
-0.122 logMAR
Standard Error 0.0055

Adverse Events

Pretreatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

PRECISION1 Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

PRECISION1 Systemic

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Clariti 1-Day Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Clariti 1-Day Systemic

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sr. Project Lead, CDMA Vision Care

Alcon Research, LLC

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER